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Abstract 
 
Context. Somatostatin analogues are commonly used to relieve symptoms in 
malignant bowel obstruction (MBO) but are more expensive than other anti-secretory 
agents.  
Objective. To evaluate the evidence of effectiveness of somatostatin analogues 
compared to placebo and/or other pharmacological agents in relieving vomiting in 
patients with inoperable MBO.  
Method. MEDLINE, EMBASE, CINAHL, The Cochrane Controlled Trials 
Register databases were systematically searched; reference lists of relevant articles 
were hand-searched. Cochrane risk of bias tool was used.  
Results. The search identified 420 unique studies. Seven randomised controlled 
trials (RCTs) met the inclusion criteria (six octreotide studies; one lanreotide); 220 
people administered somatostatin analogues and 207 placebo or hyoscine 
butylbromide. Three RCTs compared a somatostatin analogue with placebo and four 
with hyoscine butylbromide. Two adequately powered multicentre RCTs with a low 
Cochrane risk of bias reported no significant difference between somatostatin 
analogues and placebo in their primary endpoints. Four RCTs with a high/unclear 
Cochrane risk of bias reported that somatostatin analogues were more effective than 
hyoscine butylbromide in reducing vomiting.  
Conclusion. There is low-level evidence of benefit with somatostatin analogues in 
the symptomatic treatment of MBO. However, high level evidence from trials with 
low risk of bias found no benefit of somatostatin analogues for their primary outcome. 
There is debate regarding the clinically relevant study endpoint for symptom control 
in MBO and when it should be measured. The role of somatostatin analogues in this 
clinical situation requires further adequately powered, well designed trials with agreed 
clinically important endpoints and measures. 
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1. Introduction 
 
Malignant bowel obstruction (MBO) is a complication of abdominal and pelvic 
malignancies. (1, 2, 3) It is reported to occur in 10% to 50% of patients with ovarian 
cancer and up to 15% of patients with gastrointestinal cancers. (1, 4) The International 
Conference on MBO and Clinical Protocol Committee proposed the following 
specific definition criteria for MBO: “(a) Clinical evidence of bowel obstruction, (b) 
Bowel obstruction beyond the Ligament of Treitz, (c) Intra-abdominal primary cancer 
with incurable disease and (d) Non-intra-abdominal primary cancer with clear intra-
peritoneal disease”. (5) 
In MBO, mechanical obstruction occurs due to internal or external gastrointestinal 
(GI) tract malignancy, or functional occlusion from infiltration of bowel muscle or GI 
nerves by tumour thus preventing transit of food and fluids through the GI tract. (1) 
As a consequence unabsorbed secretions and oral intake accumulate in the GI tract 
and cause symptoms associated with MBO. These include nausea, vomiting, pain, 
abdominal distension and constipation. (6 - 11)  
Management of MBO depends on the location of obstruction, the goals of 
treatment and the prognosis. (1) When appropriate, surgical intervention including 
bowel resection, stoma formation or endoscopic stenting is offered in the first 
instance. (12) When surgical approaches are not appropriate, symptom-directed 
treatment aimed at reducing symptoms of MBO and optimising quality of life 
becomes the main priority. (13, 30) This may include nasogastric tube or venting 
gastrostomy insertion; or medications to reduce GI secretions, emesis and pain.  
Several studies have reported that dexamethasone, prednisolone, hyoscine 
butylbromide (scopolamine butylbromide), somatostatin analogues and 
chlorpromazine can be effective in relieving the symptoms of MBO, with the main 
outcomes being control of nausea, vomiting, pain or resolution of obstruction. (14-18) 
Palliative care guidelines often recommend the use of metoclopramide as a prokinetic 
agent in partial MBO (without colicky pain) or hyoscine butylbromide and/or 
somatostatin analogues as anti-secretory/ anti-spasmodic agents in complete MBO. 
(19, 20, 54, 55, 56)  
The most commonly used somatostatin analogue is octreotide, first developed in 
1979. Lanreotide and pasireotide are alternatives. Somatostatin analogues have 
similar physiological activity to the natural hormone somatostatin. Their mechanism 
of action includes splanchnic blood vessel vasoconstriction; reduction of secretions by 
the intestine and pancreas; increased GI absorption of water and electrolytes; and 
changes in bowel transit. (6, 21) 
As somatostatin analogues are more expensive than other anti-secretory agents 
used in MBO, (17) and to help clinicians make appropriate treatment decisions, it is 
important that the effectiveness of octreotide as compared to other pharmacological 
agents is determined. There are currently no systematic reviews evaluating the 
effectiveness of somatostatin analogues with placebo or other pharmacological agents 
in MBO. (9, 22 - 25)  
The objective of this systematic review is to evaluate the evidence of effectiveness 
for somatostatin analogues as compared to placebo, and other pharmacological agents 
in reduction of vomiting as a primary outcome and reduction of pain and abdominal 
distension as secondary outcomes in patients with inoperative MBO. The review will 
also report on systematically collected side effects of somatostatin analogues.  
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2. Methods 
 
This systematic review was conducted and reported in accordance with an a priori 
protocol which conformed to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses protocols (PRISMA-P) 2015 guidelines, (26, 68) and was 
prospectively registered with International Prospective Register of Systematic 
Reviews (PROSPERO) on 2nd May 2015; registration number: CRD42015020207. 
 
2.1 Search strategy 
 
A comprehensive search of different electronic databases using a combination of 
medical subheadings (MeSH) terms and free text was carried out to identify potential 
studies for inclusion in the review. The retrieval started from 1979, when somatostatin 
analogues were first clinically used, to August 2015 (the search date). The following 
databases were searched: MEDLINE, EMBASE, CINAHL and The Cochrane 
Controlled Trials Register. Other sources such as the registers of controlled trials in 
progress and conference proceedings were also searched. Reference lists of relevant 
articles were hand searched. The MEDLINE search strategy (table 1) was adapted to 
other databases. 
 
Table 1. Search strategy in Medline 
 
 
 
 
No. Query 
#1 (octreotide or lanreotide or pasireotide).mp 
#2 Sandostatin*.mp. 
#3 ("201995" or 201-995 or RWM8CCW8GP or "83150769" or 83150-76-9).mp. 
#4 #1 or #2 or #3 
#5 exp intestinal obstruction/ 
#6 ((intestin* or bowel*) adj3 (obstruct* or block*)).mp. 
#7 #5 or #6 
#8 exp neoplasm/ 
#9 (neoplasm* or tumo?r* or cancer* or malignan*).mp. 
#10 #8 or #9 
#11  #4 and #7 and #10 
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2.2 Eligibility and selection criteria 
 
Inclusion criteria: (a) Randomised controlled trials and quasi-randomised 
controlled trials that compared somatostatin analogues with placebo and/or other 
pharmacological agents; consecutive cohort studies were included for toxicity 
reporting over baseline where toxicity was systematically collected prospectively; (b) 
adults, aged 18 years and over, with inoperable MBO; (c) evaluated change in 
symptoms of inoperable MBO; (d) no study setting, language or publication status 
restrictions were imposed.  
Exclusion criteria: Studies that compared somatostatin analogues with 
decompression of the gut by surgery, nasogastric tube (NGT), venting gastrostomy, or 
stenting. 
Two reviewers (GPO & EGB) independently performed eligibility assessment of 
identified studies using the inclusion and exclusion criteria. Full papers were retrieved 
for those fulfilling the criteria, and for publications for which eligibility could not be 
assessed on the basis of the titles and abstracts alone. These two reviewers then 
assessed the full text of all potentially relevant studies. Disagreements or 
discrepancies at all stages were resolved by consensus and with recourse to a third 
reviewer (JWB), if necessary. The reasons for excluding a full text study are shown in 
the PRISMA flow chart (Figure 1). 
 
2.3 Data extraction, assessment and analysis 
	
Two reviewers (GPO and EGB), independently extracted data from the included 
studies. Participants’ characteristics, interventions,	controls	and	outcomes were 
extracted from the included studies. Discrepancies were resolved through discussions 
with a third reviewer (JWB).  
 
2.4 Risk of bias in individual studies 
 
Two reviewers (GPO and EGB) determined the risk of bias in individual studies 
using the Cochrane risk of bias tool (see Appendix 1). (27) Six domains of the study 
design and reporting were assessed: random sequence generation for randomisation, 
allocation concealment, blinding of participants and personnel, blinding of outcome 
assessment and selective reporting (27). With this tool, studies are classified as high, 
unclear (where the domains were not clearly described) or low risk of bias (27).  
 
3. Results 
 
3.1 Studies included 
 
We identified 420 unique studies through the searches, and examined full text of 
23 studies. Seven RCTs, representing 427 participants met our inclusion criteria 
(Figure 1).  
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Figure 1: Flowchart of study selection based on Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 
  
 
 
3.2 Characteristics of the studies included 
 
All studies were RCTs comparing a somatostatin analogue (six octreotide; one 
lanreotide) with either placebo (7, 28, 29) or hyoscine butylbromide (8, 16, 17, 24). 
Three RCTs compared a somatostatin analogue with placebo, two octreotide (7, 28) 
and one lanreotide. (29) Four RCTs compared octreotide with hyoscine butylbromide. 
(8, 16, 17, 24) A somatostatin analogue was administered to 220 participants, and 
placebo or hyoscine butylbromide to 207 (tables 2 and 3).  
Five trials were multi-centre, (7, 16, 17, 28, 29) and two trials were single centre 
studies. (8, 24,) Five studies were conducted in Europe, (, 16, 17, 24, 28, 29) one in 
Australia (7) and one in China. (8)  
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Table 2: Overview of methods and findings of included Phase 3 studies which were designed to test efficacy and recruited to power 
	
	
Study 
 
Setting Participants 
characteristics 
Intervention Comparator Outcome Measure Main results Adverse 
effects 
Risk of 
bias 
Trials with documented adequate power (≥80%) 
Currow DC, et 
al.7 Double-
Blind, Placebo-
Controlled, 
Randomized 
Trial of 
Octreotide in 
Malignant 
Bowel 
Obstruction. 
2015 
12 palliative 
care service 
networks in 
Australia. 
Recruited from 
Aug 2008 to 
May 2012 
87 adults 
patients with 
vomiting 
secondary to 
inoperable 
MBO and 
where further 
anticancer 
treatments were 
not immediately 
appropriate. 
Subcutaneous 
infusion of octreotide (600 
mcg/24 hours); n=45 
 
Both groups received 
standardized therapies: 
(regular parenteral 
dexamethasone 
[8 mg/24 hours], ranitidine 
[200mg/24 hours], 
and hydration [10-20 
mL/kg/day unless overtly 
dehydrated 
at study entry). 
Placebo 
(subcutaneous 
infusion of 
normal 
saline); n=42 
1. Primary outcome: number of days free 
of vomiting as reported daily by patients 
measured 72 hours after the first 
administration of study medications. 
2. Secondary outcomes:   
- Patient rated Global Impression of 
Change;  
- The number of patient-reported episodes 
of vomiting;  
- Episodes of vomiting per day,  
- Survival;  
- Nausea;  
- Brief Pain Inventory  
- Functional status (Australia-modified 
Karnofsky Performance 
Status ) scale;  
- Protocol defined as-needed symptom 
1. Primary outcome:  
No statistically significant 
difference in: 
- The number of days free of 
vomiting between groups (P=0.71); 
- Total number of people free of 
vomiting for all 72 hours 
(octreotide, n=17 and placebo, n 
=14; P=0.67)  
- Mean (SD) number of days free of 
vomiting in each group (1.87 [1.10], 
octreotide and 1.69 [1.15], placebo; 
P=0.47). 
2. Secondary outcomes:  
- Both groups showed significant 
decrease in the mean unadjusted 
No NCI 
CTCAE	
grade 3 
or 4 
toxicities 
Low in 
all 6 
domains 
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control medications. number of vomiting episodes 
between baseline and Day1;  
- Adjusted multivariate regression 
analysis: the octreotide group 
experienced significant reduction in 
the number of episodes of vomiting 
compared with the placebo group 
(IRR=0.40; 95% CI: 0.19-0.86; 
P=0.019). 
- Global Impression of Change: 
Both groups reported a positive 
daily change in outlook; 31 of 42 
(74%, octreotide) and 31 of 37 
(84%, placebo) rated their GIC > 0. 
Both groups were likely to report a 
positive daily change in outlook 
(OR=1.8; 95% CI: 1.39-2.36; P < 
0.001) but there was no difference 
between the groups (P > 0.75).  
- No difference in pain and nausea 
(P=0.37) between the groups on any 
day 
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- People in the octreotide group 
were 2.02 (P=0.004) times more 
likely to be administered hyoscine 
butylbromide each day compared to 
the placebo group. By study end, 
the OR between groups rose to 3.24 
(95% CI: 1.06 - 9.96; P=0.041). The 
average number of 
doses/participant/group at study end 
was 0.51 (octreotide) and 0.17 
(placebo). 
- The median performance status in 
both groups was 50 
- No difference in survival between 
groups at last census date 
(HR=1.24; 95% CI: 0.81 - 1.92; 
P=0.33). 
	
	
	
	
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 10	
	
Study 
 
Setting Participants 
characteristics 
Intervention Comparator Outcome Measure Main results Adverse 
effects 
Risk of 
bias 
Mariani P, et al 
29 Symptomatic 
treatment with 
lanreotide 
microparticles 
in inoperable 
bowel 
obstruction 
resulting from 
peritoneal 
carcinomatosis: 
a randomized, 
double-blind, 
placebo-
controlled 
phase III study. 
2012 
22 hospitals 
across 
Belgium, 
France, and the 
Netherlands. 
Recruitment 
was between 
24/09/2003 and 
15/09/2008. 
80 adults, with 
peritoneal 
carcinomatosis 
who had an 
inoperable 
MBO and were 
experiencing 
two or more 
episodes of 
vomiting per 
day or had an 
NGT. They 
were withdrawn 
from the study 
if NGT was 
inserted during 
the 1st 7 days 
of the study. 
Double-blind phase (10 
days): Day 1: A single 
intramuscular lanreotide 
microparticles formulation 
30mg injection.; n=43 (28 of 
whom had NGT at baseline) 
 
Open-label phase (n=59) 
Lanreotide every 10 days 
until they decided to stop 
treatment or died.                      
 
Concomitant treatments were 
standardized at baseline to 
ensure comparability of 
treatment groups.  
 Placebo (as 
intramuscular 
injection); 
n=37 (23 of 
whom had 
NGT at 
baseline) 
1. Primary outcome:  
- Proportion of patients with one or fewer 
vomiting episodes/day at day 7 or who had 
no recurrence of vomiting after NGT 
removal for 3 consecutive days during 
days 1 through 7 in both cases). (As 
assessed from diary card information)            
2. Secondary outcomes:  
- Changes from baseline in daily vomiting 
frequency (patients without NGT at 
baseline) or secretion volumes from NGT 
(patients with NGT at baseline);  
- Number of nausea episodes;  
- Abdominal pain intensity;  
- Well-being;  
- Number of days without vomiting;  
- Time to onset of symptom improvement;  
- Duration of symptom relief.   
1. Primary outcome:  
More patients receiving lanreotide 
than placebo were achieved 
primary outcome (41.9% [n=43] vs 
29.7% [n=37]) for the intent-to-
treat (ITT) population on the basis 
of patient reports diary cards, but 
the difference between the groups 
was not statistically significant 
(odds ratio, 1.75; 95% CI, 0.68 to 
4.49; P=0.24) 
2. Secondary outcomes:  
- Statistical significance for the 
corresponding supportive per 
protocol analysis (57.7% [n=26] vs 
30.4% [n=23]; P<0.05) and ITT 
analysis, on the basis of 
investigators’ assessments (50% 
Dry 
mouth, 
Mild 
Diabetes 
Mellitus 
Low in 4 
domains, 
high in 1 
domain 
and 
unclear 
in 1 
domain 
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(End points were assessed by visits 
scheduled at days 0, 3, 7, 10 (double-blind 
phase), and 20 (open label phase), 
Patients recorded symptoms on diary 
cards. A clinical examination was 
performed at all visits; information 
on adverse events (AEs) was collected at 
all visits except day 0.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[n=43] vs 28.6% [n=37]; P<0.05);  
- Wellbeing: Using pre-specified 
analyses, differences between 
groups were significant for days 3 
(difference in VAS 8.8 mm; 95% 
CI, 0.4 to 17.2 mm; P=04), 6 
(difference in VAS 10.4 mm; 95% 
CI, 0.6 to 20.2 mm; P=0.004), and 
7 (difference in VAS: 13.2 mm; 
95% CI, 3.3 to 23.1 mm; P=0. 01), 
but the treatment difference 
between overall means was not 
significant (P=0.07). 
- No significant differences were 
observed for other secondary 
endpoints. 
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Table 3: Overview of methods and findings of included Phase 2 studies which were not designed to test efficacy (no power calculation) 
and/or did not recruit to power 
 
Study 
 
Setting Participants 
characteristics 
Intervention Comparator Outcome Measure Main results Adverse 
effects 
Risk of 
bias 
Trials with unstated or inadequate power  
Mercadante S, 
et al17 
Comparison of 
octreotide and 
hyoscine 
butylbromide 
in controlling 
gastrointestinal 
symptoms due 
to malignant 
inoperable 
bowel 
obstruction. 
2000 
Home care and 
surgical or 
oncological 
ward, in 
consultation 
with the 
palliative 
care team in 
Italy 
18 patients with 
inoperable 
MBO received 
intervention or 
comparator 
drug.  
15 analysed 
Octreotide 300 mcg/24 hours 
subcutaneously; n=9 
Hyoscine 
butylbromide 
60 mg/24 
hours; n=6 
1. Primary outcome:  
- Reduction in the number of episodes of 
vomiting at T0, T1 [24hours], T2 
[48hours] & T3 [72hours]. 
2. Secondary outcome: 
- Intensity of nausea, drowsiness, pain 
measured at the beginning of treatment 
and 24 hours, 48 hours, and 72 hours using 
a Likert scale 0 to 4: 
- Daily amounts of fluids administered 
intravenously or subcutaneously were also 
documented. 
 
1. Primary outcome:  
Significant difference in episode of 
vomiting between the groups at T1 
(Mean [SE] of episode of vomiting 
of 1.3[0.5] in the octreotide and 
4.3[0.8] in the group Hyoscine 
butylbromide, P=0.01) and T2 
(Mean [SE] of episode of vomiting 
of 0.4[0.2] in the octreotide group 
and 2.8[0.7] hyoscine 
butylbromide, P=0.004). No 
significant difference at reported at 
T3 (Mean [SE] of episode of 
vomiting of 1.0[0.6] in the 
None 
stated  
Unclear 
in all 6 
domains 
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octreotide group and 2.4[0.7] in 
the hyoscine butylbromide, P>0.5). 
2. Secondary outcomes:  
- Significant reduction in the 
intensity of nausea in octreotide 
group at T1, T2 and T3 (P=0.01) 
and significant difference between 
the groups at T2 and T3 (P=0.02 
and 0.03, respectively), No 
significant difference at T1 
 - No significant changes in dry 
mouth, drowsiness and colicky pain 
at T1, T2 and T3. 
-Continuous pain was significantly 
lower in the octreotide group than 
the hyoscine butylbromide group at 
T1 (p<0.05), and at T2 (P<0.01). 
There was no significant difference 
at T3. 
-Drowsiness was lower in the 
hyoscine butylbromide group 
compared to the octreotide group at 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
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T2 (p=0.04). There was no 
significant difference at T1 and T3 
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Study 
 
Setting Participants 
characteristics 
Intervention Comparator Outcome Measure Main results Adverse 
effects 
Risk of 
bias 
Ripamonti C, et 
al.16 Role of 
octreotide, 
scopolamine 
butylbromide, 
and hydration 
in symptom 
control of 
patients with 
inoperable 
bowel 
obstruction and 
nasogastric 
tubes: a 
prospective, 
randomized 
trial. 2000 
Patients were 
recruited from 
Milan 
(Oncological 
Surgery 
Divisions of 
the National 
Cancer 
Institute) and 
Palermo (home 
care), Italy. 
17 patients with 
NGT and 
inoperable 
MBO 
Octreotide 300 mcg/ 24hrs 
for 3 days by a continuous 
subcutaneous infusion by 
means of a syringe driver; 
n=9 (4 in Milan, hospital 
care and 5 in Palermo, home 
care). 
Hyoscine 
(Scopolamine) 
butylbromide, 
60 mg/24 
hours for 3 
days by a 
continuous 
subcutaneous 
infusion by 
means of a 
syringe driver; 
n=8. (3 in 
Milan hospital 
care and 5 in 
Palermo home 
care) 
1. Primary outcome: daily 
volume of GI secretions through 
a NGT, 
2. Secondary outcomes:  
- The intensity of: continuous 
pain; colicky pain; nausea: dry 
mouth; thirst; dyspnoea; feeling 
of abdominal distension; and 
drowsiness at (T0) and then 
daily for 3 days (T1, T2, T3). 
1. Primary outcomes:  
- NGT secretion: There was a significant 
secretion reduction in the patients treated 
with octreotide at T2 (P=0.016, 95% CI 
319.5–950.5), and at T3 (P=0.020, 95% CI 
298.2–861.7). (Efficacy between the groups 
was compared in only 10 patients) 
2. Secondary outcomes:  
- No significant difference in continuous and 
colicky pain between the octreotide group 
and the hyoscine butylbromide group.  
- Nausea intensity in the 5 home care 
patients treated with octreotide at T2 was 
lower (P=0.05) compared to 5 home care 
patients on hyoscine butylbromide.  
- There was no relation between the intensity 
of nausea and the octreotide or hyoscine 
butylbromide, treatment in the hospitalized 
patients. 
None 
stated 
Unclear 
in 4 
doamins, 
low in 1 
domain 
and high 
in 1 
domain 
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- No significant changes were observed in 
dry mouth, thirst, drowsiness, intensity of 
dyspnoea and feeling of abdominal 
distension. 
 
Study 
 
Setting Participants 
characteristics 
Intervention Comparator Outcome Measure Main results Adverse 
effects 
Risk of 
bias 
Peng X et al8 
Randomized 
clinical trial 
comparing 
octreotide and 
scopolamine 
butylbromide 
in symptom 
control of 
patients with 
inoperable 
bowel 
obstruction due 
to advanced 
ovarian cancer.  
Departmentof 
general 
surgery, Qilu 
Hospital of 
Shandong 
University, 
China between 
January 2010 
and December 
2013. 
96 patients with 
recurrent 
ovarian cancer 
and inoperable 
MBO; life 
expectancy 
greater than 2 
months. 
 
 
Octreotide 300 mcg/24 hours 
by a continuous subcutaneous 
infusion; n=48. 
 
Concomitant treatment in both 
groups included NG tube and 
intravenous fluids. 
Hyoscine 
(scopolamine) 
butylbromide 
60 mg/24 
hours by a 
continuous 
subcutaneous 
infusion; 
n=49. 
1. Outcomes (NB: no stated 
primary outcome):  
- NGT secretions measured or 
the number of episodes of 
vomiting at (T0), 24 hours 
(T1), 48 hours (T2), and 72 
hours (T3).                                     
- Intensity of nausea (T0), 24 
hours (T1), 48 hours (T2), and 
72 hours (T3); - Dry mouth;  
- Drowsiness;   
- Continuous pain and colicky 
pain. 
1. Primary outcomes:  
- NGT secretions in the octreotide group 
were significantly less than that in the 
hyoscine butylbromide group at T1 
(Mean[SD] volume in octreotide group of 
563.6[315.1] and hyoscine butylbromide 
group of 1,206.9[278.2]; p<0.05), T2 
(Mean[SD] volume in octreotide group of 
355.4[205.4] and hyoscine butylbromide 
group of 808.5[312.6]; p<0.05), and T3 
(Mean[SD] volume in octreotide group of 
298.5[189.2] and hyoscine butylbromide 
group of 783.4 [258.6];P<0.05). 
- The number of episodes of vomiting in 
the octreotide group was significantly less 
None 
stated 
Unclear 
in 4 
domains 
and low 
in 2 
domains 
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2015 than that in the hyoscine butylbromide 
group (P<0.05) at T1 (Mean[SD] volume 
in octreotide group of 1.5[0.3] and 
hyoscine butylbromide group of 4.1[0.7]; 
P<0.05) and T2 (Mean[SD] volume in 
octreotide group of 0.5 [0.3] and hyoscine 
butylbromide group of 2.3 [0.6]; P<0.05). 
No statistically significant difference at T3 
(Mean[SD] volume in octreotide group of 
1.2[0.5] and hyoscine butylbromide group 
of 2.0[0.8]; P>0.05).   
2. Secondary outcomes:  
- Significant reductions in the number of 
episodes of vomiting in the octreotide 
group from baseline at T1, T2, and T3 
(P<0.05), whereas the reduction from 
baseline was significant only at T3 in the 
hyoscine butylbromide group (P<0.05).  
- The intensity of nausea was significantly 
lower in the octreotide group than in the 
hyoscine butylbromide group at T2 and T3 
(P<0.05).  
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-Continuous pain values were significantly 
lower in the octreotide group than in the 
scopolamine butylbromide group at T2 
and T3 (P<0.05).   
- No significant changes were observed in 
dry mouth, drowsiness, and colicky pain. 
 
Laval G et al28 
SALTO: a 
randomized, 
multicenter 
study assessing 
octreotide LAR 
in inoperable 
bowel 
obstruction. 
2012 
Multicentre 
study in 18 
centres in 
France, 
between 
November 
2005 and 
September 
2008. 
64 adults with 
inoperable 
symptomatic 
MBO due to 
peritoneal 
carcinomatosis 
of any origin; 
life expectancy 
greater than 1 
month. 
(Planned to 
recruit 102 
patients). 
Octreotide 600 mcg/24 hours 
on days 1 to 6)  
Intramuscular octreotide LAR 
30mg on days 1, 29, 57); 
n=32. 
 
Concomitant treatment in both 
groups: methylprednisolone 3-
4mg/kg/24 hours intravenous 
bolus on days 1-6. 
Placebo on 
days 1 to 6; 
n=32. 
(Matching 
Intramuscular 
placebo to 
immediate-
release 
octreotide and 
octreotide 
LAR.  
1. Primary outcome:  
- Proportion of patients at day 
14 in each arm with treatment 
success: Absence of a 
nasogastric tube, and vomiting 
less than twice per day and no 
use of anticholinergic agents. 
1. Primary outcome:  
- Treatment success at day 14 was 
achieved in 12/32 and 9/32 patients in the 
octreotide and placebo arms, respectively.  
No statistical analysis 
Severe 
hypergly
caemia, 
(n=1) 
injection 
site 
erythema 
(n=1), 
mild 
local 
reaction 
(n=1) 
High in 3 
domains, 
low in 2 
domains 
and 
unclear 
in one 
domain  
Study 
 
Setting Participants 
characteristics 
Intervention Comparator Outcome Measure Main results Advers
e effects 
Risk of 
bias 
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Mystakidou K 
et al24 
Comparison of 
octreotide 
administration 
vs conservative 
treatment in the 
management of 
inoperable 
bowel 
obstruction in 
patients with 
far advanced 
cancer: a 
randomized, 
double blind, 
controlled 
clinical trial. 
2002 
Palliative unit 
in a hospital, 
Athens, 
Greece. 
68 adults with 
advance cancer, 
not for further 
anti-tumour 
treatment, 
diagnosed with 
bowel 
obstruction. 
Octreotide 600 - 800 
mcg/24 hours; n=34.  
 
Concomitant treatment in 
both groups included 
Chlorpromazine 15–25 
mg/24 hours 
subcutaneously.  
Hyoscine 
butylbromide 
60–80 mg/24 
hours 
subcutaneously; 
n=34. 
1. Primary outcome: Nausea scored as 
1(mild), 2(average), 3(severe) and the 
number of vomiting episode/day. 
Measured at T1 (baseline), T2 (day 3), 
T3 (day 6) and T4 (1 day before death). 
2. Secondary outcomes: pain intensity 
(using visual analogue scale 0-10); 
fatigue (reported as minor or major); 
and anorexia (minor or major). 
In addition electrolyte measurements on 
T1, T2 and T3. 
1. Primary outcomes:  
- Mean percentage change from 
T1 to T2 of nausea scores and 
vomiting episodes were 
significantly different between 
the groups (nausea: octreotide 
group 93.4% and hyoscine 
butylbromide 84.2%; p=0.007 
and episodes of vomiting 
octreotide group 82.8% and 
hyoscine butylbromide 67.0%; 
p=0.003). There was no 
significant difference between 
the groups at T3 (p=0.45) and T4 
(p=0.84). 
2. Secondary outcomes:  
- Pain: No significant difference 
between the groups at T1 to T2, 
T1 to T3 and T1 to T4.  
- Fatigue and anorexia: 
Octreotide group showed 
significantly higher improvement 
Minor 
skin 
reaction 
(n=7) 
Unclear 
in 5 
domains 
and low 
in 1 
domain  
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than the hyoscine butylbromide 
group at T1 to T2, T1 to T3 and 
T1 to T4.  
 
	
	
Abbreviations: NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Effects, MBO: Malignant Bowel Obstruction, ITT: 
Intention-to-treat, NGT: Nasogastric Tube, AE: Adverse Events, mcg: micrograms, mg: milligrams, VAS: Visual Analogue Scale. 
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3.3 Effectiveness of somatostatin analogues as compared to placebo and/or other 
pharmacological agents 
 
Due to differences in the interventions and outcome measures across the included 
studies a meta-analysis was not possible. A narrative analysis was therefore 
performed (tables 2 and 3).  
 
3.3.1 Effect of somatostatin analogues on vomiting 
 
3.3.1.1 Placebo comparator studies 
Placebo controlled trials are imperative when there is no gold-standard, evidence-
based therapy. (69) This is the case for somatostatin analogues. 
Two studies, one octreotide and one lanreotide, showed no significant difference 
between a somatostatin analogue and placebo for their primary endpoint. (7, 29) 
These studies included 87, (7) and 80 (29) participants. The octreotide vs placebo 
study found no statistically significant difference in the number of days free of 
vomiting (the primary endpoint) between the groups (P=0.71). It also found no 
statistical difference in the mean number of days free of vomiting in each group 
(mean [SD] number of days free of vomiting in each group (1.87 [1.10], octreotide 
and 1.69 [1.15], placebo; P=0.47); and total number of people completely free of 
vomiting for 72 hours (octreotide, n=17 and placebo, n=14; P=0.67). (7) A 
multivariate regression analysis however showed a significant reduction in the 
number of episodes of vomiting in the octreotide compared with placebo group. In the 
Global Impression of Change, both groups reported a positive daily change in outlook 
but there was no difference between the groups (P>0.75). (7)  
In the lanreotide vs placebo study, (29) a single dose of intramuscular lanreotide 
microparticles was shown to be no better than placebo (41.9% [n=43] vs 29.7% 
[n=37]; p=0.24) with regard to the proportion of patients with one or fewer vomiting 
episode/day or no recurrence of vomiting after NGT removal for 3 consecutive days 
(the primary endpoint), using an intention to treat analysis (ITT) on day 7. There was 
however statistical significance for the corresponding per protocol analysis (57.7% 
[n=26] vs 30.4% [n=23]; P<0.05) and ITT analysis, on the basis of investigators’ 
assessments (50% [n=43] vs 28.6% [37]; P<0.05). (29) Due to off-protocol change of 
concomitant of treatments standardized at baseline and missing data 39% of 
participants were excluded from the per protocol analysis. (29)   
Although the phase II RCT that used a combination of immediate release 
octreotide and octreotide LAR or placebo met inclusion criteria, it did not complete 
recruitment. (28) Only 64 of the planned 102 participants were enrolled in the study, 
28 of whom withdrew from the study by day 14. Furthermore, a comparative analysis 
was not carried out but it was reported that at day 14, 38% and 28% of patients were 
successfully treated with somatostatin analogues and placebo respectively. (28)  
 
3.3.1.2 Active comparator studies 
Four studies reported significant reduction in episodes of vomiting or NGT 
secretions in the octreotide group as compared to the hyoscine butylbromide group. 
(8, 16, 17, 24) Two of the studies measured the episodes of vomiting, (17, 24) one 
measured both episodes of vomiting and NGT secretions, (8) and one measured the 
volume of NGT secretions. (16) The number of participants in the four studies ranged 
from 17 to 96.  
One of the studies reported a significant difference in mean percentage change 
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from baseline of episodes of vomiting (octreotide group 82.8% and hyoscine 
butylbromide group 67%; p=0.007) and nausea scores (octreotide group 93.4% and 
hyoscine butylbromide group 84.2%; p=0.003) between the groups from baseline to 
day 3, in favour of the octreotide group. This difference was however not sustained on 
day 6 (p=0.45) or on the day before death (p=0.84). (24) Another study that measured 
episodes of vomiting reported significantly greater reduction in the octreotide group 
as compared to hyoscine butylbromide group at 24 hours (mean [SE] of episode of 
vomiting of 1.3 [0.5] in the octreotide and 4.3 [0.8] in the group Hyoscine 
butylbromide; P=0.01) and 48 hours (mean [SE] of episode of vomiting of 0.4 [0.2] in 
the octreotide group and 2.8 [0.7] hyoscine butylbromide; P=0.004). There was 
however no difference between the groups at 72 hours (mean [SE] of episode of 
vomiting of 1.0 [0.6] in the octreotide group and 2.4 [0.7] in the hyoscine 
butylbromide, P>0.5). (17) For the study that measured NGT secretions data from 
only 10 home care patients were analysed. Octreotide, compared to hyoscine 
butylbromide, significantly reduced NGT secretions at 48 hours (P=0.016, 95% CI 
319.5–950.5), and at 72 hours (P=0.020, 95% CI 
298.2–861.7). (16) The study that measured both NGT secretion and episodes of 
vomiting reported that NGT secretions in the octreotide group were significantly less 
than in the hyoscine butylbromide group at 24 hours (mean [SD] volume in octreotide 
group of 563.6[315.1] and hyoscine butylbromide group of 1,206.9[278.2]; p<0.05), 
48 hours (mean [SD] volume in octreotide group of 355.4[205.4] and hyoscine 
butylbromide group of 808.5[312.6]; p<0.05) and 72 hours (mean [SD] volume in 
octreotide group of 298.5[189.2] and hyoscine butylbromide group of 783.4 
[258.6];P<0.05) and the episodes of vomiting at 24 hours (mean [SD] volume in 
octreotide group of 1.5[0.3] and hyoscine butylbromide group of 4.1[0.7]; P<0.05) 
and 48 hours (mean [SD] volume in octreotide group of 0.5 [0.3] and hyoscine 
butylbromide group of 2.3 [0.6]; P<0.05) but no statistically significant difference at 
72 hours (mean [SD] volume in octreotide group of 1.2[0.5] and hyoscine 
butylbromide group of 2.0[0.8]; P>0.05). (8) 
 
3.3.2 Effect of somatostatin analogues on abdominal pain intensity and abdominal 
distension  
With regard to secondary outcomes, six of the included studies measured 
abdominal pain intensity. Four studies reported no significant difference in pain, (7, 
16, 24, 29) however in one of the studies, patients receiving octreotide had more 
hyoscine butylbromide indicating that there might be an association between 
octreotide administration and colicky abdominal pain. (7)  
Two studies reported continuous pain to be significantly lower in the octreotide 
group (P<0.05) whereas there was no significant difference in colicky pain. (8, 17) 
One study measured abdominal distension and found no significant difference with 
octreotide. (16) 
 
3.3.3 Drug related adverse effects 
Four of the included RCTs reported on drug related adverse effects. (7, 24, 28, 29) 
One found no Common	Terminology	Criteria	for	Adverse	Effects (CTCAE) grade 3 
or 4 toxicities. (7) Adverse effects were reported as follows: dry mouth in 1 out of 80 
participants (29), mild diabetes mellitus in 1 out of 80 participants (29), minor skin 
reaction in 7 out of 68 participants (24), severe hyperglycaemia in 1 out of 64 
participants (28), injection site erythema in 1 out of 64 participants (28) and; mild 
local reaction in 1 out of 64 participants (28) (tables 2 and 3).  
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3.4 Risk of bias within studies 
 
The Cochrane risk of bias for the trials is shown in table 4. One trial had low risk 
of bias in all of the 6 domains, (7) another study had low risk of bias in 4 domains 
(29) five studies had high and/or unclear risk of bias in most domains (8, 16, 17, 24, 
28) 
 
Table 4: Assessment of risk of bias 
 
Study Random sequence 
generation 
Allocation 
concealment 
Blinding of 
participant 
and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting 
Currow D 
C, et al, 
2015 
 
Power 
calculations 
shown 
Low risk 
“Randomization 
schedules were 
developed for each 
site using random 
number tables, 
generated 
centrally. 
Participants were 
randomized in 
blocks of four by 
site in a 1:1 ratio.” 
Low risk 
“Site pharmacists 
who opened the 
treatment 
schedules to 
prepare the 
intervention were 
otherwise not 
involved in 
patient care. 
Syringes were 
identical in 
volume and 
color” 
Low risk 
“Clinical staff, 
assessors, and 
participants 
were all 
blinded to 
treatment 
allocations.” 
Low risk 
“Clinical staff, 
assessors, and 
participants 
were all 
blinded to 
treatment 
allocations.” 
Low risk 
“6 patients 
(6%) were 
removed 
from analysis 
due to 
protocol 
violation” 
Low risk 
“Data reported 
on pre-defined 
primary 
outcome” 
Mariani, P. 
et al, 2012 
 
Power 
calculations 
shown 
Low risk 
“Patients were 
randomly assigned 
to treatment 
according to two 
computer 
generated 
randomization lists 
created and held 
confidentially by 
the sponsor” 
Low risk 
“The sponsor 
placed the 
visually 
indistinguishable 
treatments in 
numbered 
containers and 
dispatched them 
in randomization 
blocks to study 
sites” 
Low risk 
“double-blind, 
placebo-
controlled 
investigation” 
Low risk 
“double-blind, 
placebo-
controlled 
investigation” 
Unclear risk 
16% did not 
complete the 
study 
high risk 
Although data 
reported on pre-
defined primary 
outcome 
showed no 
difference 
between 
lanreotide and 
placebo and; 
there was 
discrepancy 
between 
primary and 
supportive 
analysis the 
concluded that 
“significantly 
more patients 
receiving 30 mg 
of lanreotide 
microparticles 
than placebo 
responded to 
treatment in 
terms of 
reduced 
vomiting for 
two of the three 
analyses 
conducted”. 
Mercadante, 
S. et al, 
2000 
Unclear risk 
“Patients were 
randomly 
divided into two 
groups to receive 
octreotide (group 
O) or HB (group 
Unclear risk 
No information 
Unclear risk 
No 
information 
Unclear risk 
No 
information 
Unclear risk 
No 
information 
Unclear risk 
Primary 
outcome not 
clearly 
predefined 
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HB) treatment.” 
Ripamonti 
et al 
Unclear risk 
Randomization 
was not described 
Unclear risk 
Allocation 
concealment was 
not described 
Unclear risk 
Not described 
Unclear risk 
Not described 
Low risk 
Although 
sample was 
small there 
was not loss 
to follow up 
High risk 
Analysis of 
primary 
outcome was 
done on very 
small number of 
patients, only 
10 of the 17 
participants 
who followed 
up at home 
were analysed.  
Peng, X. et 
al, 2015 
Low risk 
“Randomization 
was achieved by 
means of 
computer 
generated random 
numbers” 
Unclear risk 
No information 
Unclear risk 
No 
information 
Unclear risk 
No 
information 
Low risk 
Only 1 of 97 
patient 
withdrew 
Unclear risk 
Primary 
outcome not 
clearly 
predefined 
Laval, G. et 
al, 2012 
High risk 
“Despite the 
process of 
randomization, a 
higher proportion 
of patients in the 
octreotide arm 
(46.4%) than in 
the placebo arm 
(21.9%) had a 
Karnofsky score 
less than 50” 
 
Unclear risk 
No information 
give 
 
High risk 
“Because 
octreotide 
LAR has a 
different 
appearance to 
the placebo, 
the nurse 
who 
administered 
the 
treatments 
was not 
blinded” 
Low risk 
“Neither the 
investigator 
nor the 
patient was 
informed of 
the patient’ s 
assigned 
group. The 
assessment of 
symptoms 
was 
performed by 
the patient 
and 
investigator” 
High risk 
28 out of 64 
(~44%) 
patients did 
complete the 
study. 
Low risk 
“The primary 
endpoint was 
determined in 
the intention 
to-treat (ITT) 
population at 
day 14.  
Mystakidou, 
et al, 2002. 
Unclear risk 
Randomization 
sequence 
generation method 
not described 
Low risk 
“The clinician 
were unaware of 
which group the 
patients were 
assigned to” 
Unclear risk 
No 
information 
Unclear risk 
No 
information 
Unclear risk 
No 
information 
Unclear risk 
15 patients 
withdrew. 
 
4. Discussion 
 
This systematic review evaluated the evidence for the effectiveness of somatostatin 
analogues as compared to placebo and/or other pharmacological agents. We identified 
seven eligible RCTs of somatostatin analogues vs placebo or hyoscine butylbromide 
for the relief of symptoms due to inoperable MBO. (7, 8, 16, 17, 24, 28, 29)  
The design, outcome measurement and timing of endpoints varied between studies. 
Therefore, as a meta-analysis was not possible, each trial’s individual contribution to 
the evidence base was evaluated. Five trials with high Cochrane risk of bias provided 
lower level evidence of benefit (8, 16, 17 24, 28) and two trials with low Cochrane 
risk of bias provided higher level evidence of no benefit. (7, 29) 
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4.1 Outcome measurement and study endpoints 
 
The primary outcome measurement varied from NGT secretion volume, to number 
of vomits per day and was measured at varying follow up time points. The choice of 
primary outcomes appeared to be empirical: as pointed out by Currow and colleagues, 
there is no agreed clinically relevant outcome measure or time-point for nausea and 
vomiting in the palliative care setting. (7, 62) Debate continues as to when a benefit 
would be expected, for how long any benefit would be sustained, and what benefit 
would be considered clinically relevant by the patients concerned and their family 
members. (59) Further, the natural history of MBO is still largely unknown; (34) 
although the placebo arms of the reported trials give important information for the 
length of follow up reported. In the studies reporting benefit, this tended to be early 
during follow up and was not sustained much beyond day 3. (8, 16, 17, 24) Even if 
this benefit was to be confirmed in subsequent studies, there is an important clinical 
question regarding whether people with vomiting due to MBO should or can be 
supported over the weeks leading up to their death by medical management alone. It 
is not known whether medical management confers net benefit, including patient 
acceptability, over gut decompression by whatever means: the trials have not been 
conducted. 
Two studies reported no difference between somatostatin analogues and placebo in 
their primary endpoints. (7, 29) One study’s primary outcome was the number of days 
free of vomiting measured at 72 hours whereas episodes of vomiting was a secondary 
outcome. (7) The reported results showed efficacy of octreotide in reducing episodes 
of vomiting but not number of days free of vomiting. The correct timing of this 
outcome measurement has been debated. (58) Whereas some authorities recommend 
that 2 to 5 days are required for octreotide to show effect, (57) from this review, 
earlier benefit, if present, was not sustained in those studies that measured outcome 
after 3 days. It has been suggested that this could be partly due to worsening 
symptoms due to disease progression. (59) The study that measured endpoint at 
baseline, day 3, day 6 and 1 day before death, found no difference between octreotide 
and hyoscine butylbromide at day 6 and 1 day before death. (24) Four studies 
measured outcome only up to 3 days, (7, 8 16, 17) one of which showed no difference 
between octreotide and hyoscine butylbromide at day 3 also suggested that the 
difference tended to be less pronounced after 3 days. (16)  
Hyoscine butylbromide was used as an as-needed therapy for colicky pain at a dose 
per participant of 0.51 for the octreotide group and 0.17 with placebo group but it is 
also an anti-secretory drug. (7) This could have therefore biased outcome in favour of 
the octreotide group. 
 
4.2 Study design 
 
4.2.1 Robustness 
There are a number of cohort studies, retrospective reviews, and single-patient 
reports that did not meet the standard required for this review. These suggest 
improvement in symptoms due to MBO with somatostatin analogues. (16-18, 31-50) 
These studies with high risk of bias do not provide robust evidence of effectiveness of 
somatostatin analogues; they are uncontrolled, have high risk of bias and do not have 
a comparator. (51) Where there is an urgent clinical need to attempt to alleviate 
distressing symptoms, there is a temptation to base practice on preliminary data. Some 
authors have advocated for balanced and practical considerations in the design, 
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conduct and interpretation of clinical research in palliative care. (59, 60, 61, 62) 
However, as Keeley urges, [64] we must be wary of the “faggot fallacy”. [65] For 
those unfamiliar with this English term, a faggot is a bundle of sticks tied together; a 
collection of pieces of weak evidence does not make them stronger for being grouped 
together. Kunz et al reported that failure to adequately conceal random allocation 
could make the apparent effects of care seem either larger or smaller than they really 
are. (69) Further, the International Conference on MBO and Clinical Protocol 
Committee advocates that high quality studies that ultimately improve symptom 
management strategies are required. (5) The Consolidated Standards of Reporting 
Trials (CONSORT) guidelines were written to help the reporting and interpretation of 
RCTS in order to minimize the risk of biased estimates of treatment effects. [66] 
Thus, in this review we have followed the Cochrane risk of bias tool, based on the 
CONSORT guidance to act as a compass through this difficult topic where there is an 
urgent need for therapeutic options at the bedside. We have reported our findings 
transparently using standard guidance. Of the seven trials, only two were a phase III 
multisite trials with adequate power to discard the null hypothesis and reached their 
required sample size. (7, 29) These were the only two with a low risk of bias in all or 
most domains assessed. It is also important to note the multisite nature of these trials. 
Single centre trials, especially smaller ones, show larger intervention effects than 
multicentre trials (67); the two small trials in this review (N=10 and N=18 of which 
only 10 were analysed (16, 17)) both showed benefit with octreotide. Multicentre 
trials tend to have a more heterogeneous population and therefore provide more 
generalizable findings, which can be more readily implemented in clinical practice. 
(71) The five studies categorized as high or unclear risk of bias had absent or 
inadequate reporting of allocation concealment, blinding, MBO diagnosis and 
evaluation of participants who were excluded due to lack of efficacy. We recognize 
that inadequate reporting of a trial may not equate to poor trial design, however, as 
Altman and colleagues stated, “Critical appraisal of the quality of clinical trials is 
possible only if the design, conduct, and analysis of RCTs are thoroughly and 
accurately described in published articles.” (73) It is therefore inevitable that more 
weight is given to the findings of the two adequately powered trials with regard to 
their primary outcome as the robust design allows more confidence in the findings. 
However, the question in both of these trials remains as to whether their respective 
primary endpoints are the most clinically relevant, and whether the empirical nature 
of both sample size calculations was adequate.  
 
4.2.2 Analysis 
The study by Mariani et al had discrepancies in the analysis of its primary 
outcome. The intention to treat (ITT) analysis showed no difference between the two 
groups, whereas the per protocol analysis and investigator’s subjective assessment of 
responders at day 7 showed efficacy in reducing vomiting. (29) In the per protocol 
analysis, the number of included participants was 39% less than the ITT population. 
(ITT: Lanreotide 43, placebo 37; per protocol: Lanreotide 26, placebo 23). (29) One 
of the most common reasons for exclusion from the per protocol population was an 
off-protocol change of concomitant of treatments standardized at baseline to ensure 
group comparability, i.e. (i) intravenous corticosteroids (ii) intravenous proton pump 
inhibitors (iii) antispasmodics or antiemetics. (29) This is likely to lead to the 
improved outcomes reported in the per protocol population. Furthermore any per 
protocol analysis is more likely to show benefit than the same study analysed on an 
intention to treat basis. (72) 
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4.3 Adverse events 
In general, somatostatin analogues appeared to be tolerated with a few mild 
adverse events and no drop outs due to toxicity reported in any of RCTs to be 
anything other than. However, it is of note that the observed increased use of hyoscine 
in the octreotide arm of the Currow et al study, in addition to risking overestimate of 
benefit in that arm, might have been due to increased colicky abdominal pain. (7)  
 
5. Limitations 
 
The main limitation of this systematic review is that a meta-analysis could not be 
performed due to differences in interventions and outcomes. Some included studies 
had a high risk of bias, but due to the paucity of RCT data in this area, we did not 
exclude trials on the basis of quality of reporting. (27)  
 It is possible that some relevant studies were missed despite a detailed search 
strategy where there were no date or language restrictions and standard methods for 
selection and data extraction were employed. 
 
6. Implications for further research 
 
There is a need for work to understand what people with nausea and vomiting due 
to MBO class as a clinically important outcome. Questions should be asked in the 
context of what makes a meaningful difference to overall function, wellbeing and 
possibilities for place of care. For example, the number and volume of vomits may 
need to be greatly reduced in order for that person to remain at home, especially if 
they live alone. As we do not have high level evidence of efficacy against placebo, 
trial equipoise remains and further placebo controlled trials are needed. This will also 
help our understanding of the natural history of MBO; misattribution of benefit to 
intervention (a recognized concern in palliative care trials, 74) will lead to 
overestimation. We also need to clarify the role of and acceptability of gut 
decompression as a more definitive measure, given that death may not ensue for 
several weeks. This better understanding would inform study design in order to 
inform clinical practice and service provision. Agreement on common outcome 
measures would help collaborative working between centres, or at least allow the 
possibility of data pooling and meta-analysis to allow our knowledge to move 
forward. Further research should be mindful that the onus is on the researchers to 
demonstrate net benefit 
 
7. Conclusions 
 
Using standardized tools for risk of bias, we found low level evidence of benefit 
with somatostatin analogues in the symptomatic treatment of MBO. However, high 
level evidence from trials with low risk of bias found no benefit for their primary 
outcome. There is debate regarding the clinically relevant study endpoint for symptom 
control in MBO. The International Conference on MBO and Clinical Protocol 
Committee calls for adequately powered, well designed trials with agreed clinically 
important endpoints and measures which can underpin recommendations for practice. 
The role of somatostatins (whether, and, if so, what) in this challenging and 
distressing clinical situation requires clarification. 
 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 28	
8. Acknowledgments 
 
We would like to acknowledge the advice and support provided by Bernadette 
Coles, Cancer Research Wales Library, in developing the search strategy. 
 
References 
	
1. Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in 
advanced cancer patients: epidemiology, management, and factors influencing 
spontaneous resolution.  Cancer Management and Research 2012;4: 159-169 	
2. Ripamonti C, Mercadante S. Pathophysiology and management of malignant 
bowel obstruction. In: D. Doyle, G.W. Hanks, N. McDonald, N. Cherny (Eds.) 
Oxford textbook of palliative medicine. 3rd ed. Oxford University Press, New 
York, 2005: 496–506 
3. Frank C. Medical management of intestinal obstruction in terminal care. Canadian 
Family Physician Le Midecin defamille canadien. 1997; 43: 259-265  
4. Mercadante S. Intestinal dysfunction and obstruction. In: Walsh D, editor. 
Palliative Medicine. Philadelphia, PA: Saunders/Elsevier, 2009:1267–1275. 
5. Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol 
committee: development of randomized trials for malignant bowel obstruction. J 
Pain Symptom Manage. 2007;34(Suppl 1):S49–S59.  
6. Ripamonti C.  Treatment and prognosis. In: Fisch M J and Bruera E, eds. 
Handbook of advanced cancer care. Cambridge, united Kingdom: The press 
syndicate of the University of Cambridge, 2003: 465-466.  
7. Currow DC, Quinn S, Agar M et al. Double-Blind, Placebo-Controlled, 
Randomized Trial of Octreotide in Malignant Bowel Obstruction. J Pain Symptom 
Manage 2015; 49: 814 - 821 
8. Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing 
octreotide and scopolamine butylbromide in symptom control of patients with 
inoperable bowel obstruction due to advanced ovarian cancer. World J Surg 
Oncol. 2015;13:50. 
9. Kubota H, Taguchi K, Kobayashi D, et al. Clinical impact of palliative treatment 
using octreotide for inoperable malignant bowel obstruction caused by advanced 
urological cancer. Asian Pac J Cancer Prev. 2013;14(12):7107-10 
10. Zhang Y, Gao Y, Ma Q et al. Randomised clinical trial investigating the effects of 
combined administration of octreotide and methylglucamine diatrizoate in the 
older persons with adhesive small bowel obstruction. Dig  Liver Dis 2006; 
38(3):188-94. 
11. Khoo D, Hall E, Motson R et al. Palliation of malignant intestinal obstruction 
using octreotide. European Journal of Cancer. 1994; 30A(1):28-30. 
12. DeBernardo R. Surgical management of malignant bowel obstruction: strategies 
toward palliation of patients with advanced cancer. Curr Oncol Rep. 2009; 
11(4):287-92. 
13. Mercadante S, Casuccio A, Mangione S. Medical Treatment for Inoperable 
Malignant Bowel Obstruction: A Qualitative Systematic Review. J Pain Symptom 
Manage. 2007;33(2):217-23. 
14. Hardy J, Ling J, Mansi J, et al. Pitfalls in placebo-controlled trials in palliative 
care: dexamethasone for the palliation of malignant bowel obstruction. Palliat 
Med 1998;12:437e442.  
15. Laval G, Girarder J, Lassauniere J, et al. The use of steroids in the management of 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 29	
inoperable intestinal obstruction in terminal cancer patients: do they remove the 
obstruction? Palliat Med 2000;14:3 -10  
16. Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine 
butylbromide, and hydration in symptom control of patients with inoperable 
bowel obstruction and nasogastric tubes: a prospective, randomized trial. J Pain 
Symptom Manage 2000;19:23 - 34.  
17. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of 
octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms 
due to malignant inoperable bowel obstruction. Support Care Cancer 2000; 8:188 
- 191.  
18. Mittal DL, Mittal A, Brosnan EA, Landman WJ. Nonopioid pharmacological 
management of malignant bowel obstruction: a New Zealand-wide survey. J 
Palliat Med. 2014 Nov;17(11):1249-55.  
19. NHS Scotland. Scottish Palliative Care Guidelines: Bowel Obstruction. Available 
from: http://www.palliativecareguidelines.scot.nhs.uk. Accessed March 25, 2015. 
20. Fraserhealth: Hospice Palliative Care Program Symptom Guidelines: Malignant 
Bowel Obstruction. Available from: 
https://www.fraserhealth.ca/media/13FHSymptomGuidelinesMalignantBowelObs
truction.pdf. Accessed March 25, 2016 
21. Murphy E, Prommer EE, Mihalyo M, Wilcock A. Octreotide. Journal of Pain & 
Symptom Management 2010; 40(1): 142-8. 
22. Allen MP, Blake JF, Bryce DK et al. Design, synthesis and biological evaluation 
of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor 
ligands. Bioorganic and Medicinal Chemistry Letters 2000; 10(6): 523–6. 
23. Ma L, Wang T, Ma B, Liu Y. Octreotide for inoperable malignant bowel 
obstruction. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: 
CD008396. DOI: 10.1002/14651858.CD008396  
24. Mystakidou K, Tsilika E, Kalaidopoulou O, et al. Comparison of octreotide 
administration vs conservative treatment in the management of inoperable bowel 
obstruction in patients with far advanced cancer: a randomized, double-blind, 
controlled clinical trial. Anticancer Res 2002; 22(2B):1187–92. 
25. Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for 
the management of bowel obstruction in patients with end-stage cancer. Support 
Care Cancer 2001; 9:223 - 233. 
26. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items 
for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 
2009; 6(7):e1000097. 
27. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included 11 studies. 
In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of 
interventions version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 
2008. Available from: http://www.cochrane-handbook.org/. Accessed 26 May 
2015. 
28. Laval G, Rousselot H, Toussaint-Martel S, et al. SALTO: a randomized, 
multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull 
Cancer 2012; 99:E1- E9. 
29. Mariani P, Blumberg J, Landau A, et al. Symptomatic treatment with lanreotide 
microparticles in inoperable bowel obstruction resulting from peritoneal 
carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J 
Clin Oncol 2012; 30:4337 - 4343. 
30. Ghoshal A, Salins N, Damani A, Deodhar J, Muckaden MA. Medical 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 30	
Management of Pediatric Malignant Bowel Obstruction in a Patient with Burkitt's 
Lymphoma and Ataxia Telangiectasia Using Continuous Ambulatory Drug 
Delivery System. J Pain Palliat Care Pharmacother. 2016 Mar;30(1):44-8. 
31. Hwang M, Pirrello R, Pu M, Messer K, Roeland E. Octreotide prescribing patterns 
in the palliation of symptomatic inoperable malignant bowel obstruction patients 
at a single US academic hospital. Support Care Cancer. 2013 Oct;21(10):2817-24. 
32. Arvieux C, Laval G, Mestrallet JP, Stefani L, Villard ML, Cardin N. Treatment of 
malignant intestinal obstruction. A prospective study over 80 cases. [French]. 
Annales de Chirurgie. 2005; 130(8):470-6. 
33. Barrelet L, Mazzocato C. Role of octreotide in the management of malignant 
intestinal obstruction. [French]. Medecine et Hygiene. 1997; 55(2169):1337-8. 
34. Chakraborty A, Selby D, Gardiner K, Myers J, Moravan V, Wright F. Malignant 
bowel obstruction: Natural history of a heterogeneous patient population followed 
prospectively over two years. Journal of Pain and Symptom Management. 2011; 
41(2):412-20. 
35. Hisanaga T, Shinjyo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, et al. 
Efficacy of octreotide acetate for malignant gastrointestinal obstruction. Annals of 
Oncology. 2008; 19 (S8):viii254-viii5. 
36. Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J. Palliation of 
malignant intestinal obstruction using octreotide. European Journal of Cancer Part 
A: General Topics. 1994; 30(1):28-30. 
37. Kilonzo I, Waldron D, Mannion E, Kromer D. A prospective evaluation of 
octreotide in the palliation of gastrointestinal symptoms. Palliative Medicine. 
2014; 28 (6):596. 
38. Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide 
(SMS201-995) in terminally Ill Japanese cancer patients with malignant bowel 
obstruction. Japanese Journal of Clinical Oncology. 2008; 38(5):354-9 
39. Tanimura K, Onda S, Mitsunobu M. [Effective made of octreotide intravenous 
administration for malignant gastrointestinal obstruction in terminal cancer 
patients]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 
2010; 37(10):1991-3. 
40. Uchino R, Kusano S, Hanada N, et al. [Clinical efficacy of octreotide acetate in 
cancer patients with malignant bowel symptoms depend on terminal stage]. Gan to 
Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 2011; 38(2):255-7. 
41. Watari H, Hosaka M, Wakui Y, et al. A prospective study on the efficacy of 
octreotide in the management of malignant bowel obstruction in gynecologic 
cancer. International Journal of Gynecological Cancer. 2012; 22(4):692-6 
42. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in 
relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993; 
7:295–9. 
43. Mangili G, Aletti G, Frigerio L, et al. Palliative care for intestinal obstruction in 
recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer 2005; 
15:830–5. 
44. Mercadante S. Bowel obstruction in home-care cancer patients: four years 
experience. Support Care Cancer 1995; 3:190–3. 
45. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel 
obstruction in terminal ovarian cancer. Gynecol Oncol 1996; 61:345–8. 
46. Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological 
treatment for reversing bowel obstruction. J Pain Symptom Manage 2004; 
28:412–6. 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 31	
47. Porzio G, Aielli F, Verna L, et al. Can malignant bowel obstruction in advanced 
cancer patients be treated at home? Support Care Cancer 2011; 19:431–3. 
48. Weber C, Zulian GB. Malignant irreversible intestinal obstruction: the powerful 
association of octreotide to corticosteroids, antiemetics, and analgesics. Am J 
Hosp Palliat Care 2009; 26:84–8. 
49. Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the 
treatment and symptomatic relief of bowel obstruction in advanced ovarian 
cancer. J Pain Symptom Manage 2005; 30:563–9. 
50. Massacesi C, Galeazzi G. Sustained release octreotide may have a role in the 
treatment of malignant bowel obstruction. Palliat Med 2006; 20:715–6. 
51. Krouse RS. The international conference on malignant bowel obstruction: a 
meeting of the minds to advance palliative care research. J Pain Symptom Manage 
2007; 34(Suppl):S1- S6. 
52. Twycross R, Wilcock A, Howard. Palliative Care Formulary 5th ed. Nottingham, 
United Kingdom: Palliative care.com ltd., 2014. 
53. Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: Twenty 
years after. Critical Reviews in Oncology/Hematology 2012; 83: 388–392 
54. Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, Copel L, Durand A.  
Recommendations for Bowel Obstruction With Peritoneal Carcinomatosis. J Pain 
Symptom Manage 2014;48:75-91 
55. Ferguson H M J, Ferguson C I, Speakman J, Ismail T. Management of intestinal 
obstruction in advanced malignancy. Annals of Medicine and Surgery 4 (2015) 
264-270 
56. Soriano A, Davis, M. Malignant bowel obstruction:Individualized treatmentnear 
the end of life. C leveland Clinical Journal of Medicine 2011; 78:3  
57. Mercadante S. Octreotide for Malignant Bowel Obstruction: Commentary on 
Currow et al. Journal of Pain and Symptom Management. 2015: 813:49 
58. Zelek A, Laval G, Asselain B. Somatostatin Analogs for Malignant Bowel 
Obstruction Resulting From Peritoneal Carcinomatosis. J Clin Oncol 2013: 
48.4634 
59. Bellavance EC, Alexander HR Jr. Palliative interventions in patients with 
peritoneal metastases and malignant bowel obstruction. J Clin Oncol 
2012;30:4290-4291.  
60. Shelby-James TM, Hardy J, Agar M, et al: Designing and conducting randomized 
controlled trials in palliative care: A summary of discussions from the 2010 
clinical research forum of the Australian Palliative Care Clinical Studies 
Collaborative. Palliat Med [epub ahead of print on August 15, 2011] 
61. Laneader A, Angelos P, Ferrell BR, et al: Ethical issues in research to improve the 
management of malignant bowel obstruction: Challenges and recommendations. J 
Pain Symptom Manage 34:S20-S27, 2007 
62. LeBlanc T W, Abernethy A P, Currow D C, BMed,  Kutner J S. Considerations in 
reporting palliative care clinical trials: Standardizing information reported and 
authorship practices. Curr Opin Support Palliat Care. 2012 Dec; 6(4): 494–499.  
63. Saxby C, Ackroyd R, Callin S, Mayland C. How should we measure emesis in 
palliative care? Palliat Med July 2007 21: 369-383 
64. Keeley P. Making the GRADE editorial. Palliat Med 2004 18: 675-65. 
65. Skrabanek P, McCormick J. Follies and Fallacies in Medicine. Glasgow: Tarragon 
Press, 1989: 30. 
66. Schulz K F, Altman D G. CONSORT 2010 Statement: updated guidelines for 
reporting parallel group randomised trials. BMJ 2010;340:c332 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 32	
67. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of 
single centre status on estimates of intervention effects in trials with continuous 
outcomes: meta-epidemiological study. BMJ 2012;344:e813  
68. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015: elaboration and 
explanation BMJ 2015; 349:g7647 
69. Kunz R, Oxman AD. The unpredictability paradox: review of empirical 
comparisons of randomised and non-randomised clinical trials. BMJ. 1998 Oct 
31;317(7167):1185-90 
70. Chiodo G T,  Tolle S W, Bevan L. Placebo-controlled trials good science or 
medical neglect? West J Med. 2000 Apr; 172(4): 271–273. 
71. Weinberger M1, Oddone EZ, Henderson WG, Smith DM, Huey J, Giobbie-
Hurder A, Feussner JR. Multisite randomized controlled trials in health services 
research: scientific challenges and operational issues. Med Care. 2001 
Jun;39(6):627-34. 
72. Chêne G, Morlat P, Leport C, et al. Intention-to-treat vs. on-treatment analyses of 
clinical trial data: experience from a study of pyrimethamine in the primary 
prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 
Trial Group. Control Clin Trials. 1998 Jun;19(3):233-48. 
73. Altman D, Schulz KF, Moher D, et al. The Revised CONSORT Statement for 
Reporting Randomized Trials: Explanation and Elaboration. Ann Intern Med. 
2001;134:663-694. 
74. Hussain JA, White IR, Langan D, et al. Missing data in randomized controlled 
trials testing palliative interventions pose a significant risk of bias and loss of 
power: a systematic review and meta-analyses. Journal of Clinical Epidemiology 
2015 in press and available on line http://www.jclinepi.com/article/S0895-
4356(15)00579-X/pdf. Accessed on 25/04/2016. 
 
 
 
  
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
	 33	
Appendix 1: Cochrane risk of bias tool 
 
Domain Support for judgement Review authors’ 
judgement 
Selection bias.     
Random sequence 
generation. 
Describe the method used to 
generate the allocation sequence in 
sufficient detail to allow an 
assessment of whether it should 
produce comparable groups. 
Selection bias (biased 
allocation to interventions) 
due to inadequate 
generation of a randomised 
sequence. 
Allocation 
concealment. 
Describe the method used to conceal 
the allocation sequence in sufficient 
detail to determine whether 
intervention allocations could have 
been foreseen in advance of, or 
during, enrolment. 
Selection bias (biased 
allocation to interventions) 
due to inadequate 
concealment of allocations 
prior to assignment. 
Performance bias.     
Blinding of 
participants and 
personnel 
Assessments should 
be made for each 
main outcome (or 
class of outcomes).  
Describe all measures used, if any, 
to blind study participants and 
personnel from knowledge of which 
intervention a participant received. 
Provide any information relating to 
whether the intended blinding was 
effective. 
Performance bias due to 
knowledge of the allocated 
interventions by 
participants and personnel 
during the study. 
Detection bias.     
Blinding of 
outcome assessment 
Assessments should 
be made for each 
main outcome (or 
class of outcomes). 
Describe all measures used, if any, 
to blind outcome assessors from 
knowledge of which intervention a 
participant received. Provide any 
information relating to whether the 
intended blinding was effective. 
Detection bias due to 
knowledge of the allocated 
interventions by outcome 
assessors. 
Attrition bias.     
Incomplete 
outcome data 
Assessments should 
be made for each 
main outcome (or 
class of outcomes).  
Describe the completeness of 
outcome data for each main 
outcome, including attrition and 
exclusions from the analysis. State 
whether attrition and exclusions 
were reported, the numbers in each 
intervention group (compared with 
total randomized participants), 
reasons for attrition/exclusions 
where reported, and any re-
inclusions in analyses performed by 
the review authors. 
Attrition bias due to 
amount, nature or handling 
of incomplete outcome 
data. 
Reporting bias.     
Selective reporting. State how the possibility of selective 
outcome reporting was examined by 
the review authors, and what was 
found. 
Reporting bias due to 
selective outcome 
reporting. 
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Other bias.     
Other sources of 
bias. 
State any important concerns about 
bias not addressed in the other 
domains in the tool. 
If particular questions/entries were 
pre-specified in the review’s 
protocol, responses should be 
provided for each question/entry. 
Bias due to problems not 
covered elsewhere in the 
table. 
 
Source: The Cochrane handbook for systematic reviews of interventions version 5.0.0 
[updated February 2008], Chapter 8, Available from: http://www.cochrane-
handbook.org/. Accessed 26 May 2015. 
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